RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Intravitreal Aflibercept Has Long-Term Benefits in Treatment of DME
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 43
SP 10
OP 10
DO 10.1177/155989771443005
UL http://mdc.sagepub.com/content/14/43/10.abstract
AB This article describes the 2-year outcomes of the Intravitreal Alfibercept Injection in Vision Impairment Due to DME [VIVID; NCT01331681] trial as well as the Study of Intravitreal Administration of VEGF Trap-Eye (BAY86-5321) in Patients With Diabetic Macular Edema [VISTA; NCT01363440]. VIVID and VISTA are both phase III, randomized, double-blind global studies in which intravitreal aflibercept was injected to treat diabetic macular edema.